About Portage Biotech
Portage Biotech is a company based in Tortola (British Virgin Islands) founded in 2013. Portage Biotech has completed 2 acquisitions, including Tarsus Rx and Tarus Therapeutics. Portage Biotech offers products and services including iNKT Platform, Adenosine Platform, and Other Programs.
- Headquarter Tortola, British Virgin Islands
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Portage Biotech Inc.
-
Annual Revenue
Not available
-
Net Profit
-$6.77 M (USD)91.02as on Mar 31, 2025
-
EBITDA
-$7.38 M (USD)59.43as on Mar 31, 2025
-
Latest Funding Round
$36.08 M (USD), Post-IPO
Sep 02, 2025
-
Investors
Not available
-
Employee Count
Not available
-
Investments & Acquisitions
Tarsus Rx
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Portage Biotech
Portage Biotech is a publicly listed company on the NASDAQ with ticker symbol ATON in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Portage Biotech
Portage Biotech offers a comprehensive portfolio of products and services, including iNKT Platform, Adenosine Platform, and Other Programs.
Develops therapies targeting cancer resistance pathways through immune activation
Focuses on novel assets for cancer treatment via adenosine modulation
Advances preclinical assets for diverse cancer resistance mechanisms
Funding Insights of Portage Biotech
Investments & Acquisitions by Portage Biotech
Portage Biotech has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Tarsus Rx and Tarus Therapeutics.
Investment portfolio details for Portage Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cancer therapeutics targeting the adenosine pathway are developed.
|
Locked | Locked | 2019 | Locked | |
|
Proprietary drugs for blepharitis treatment are developed by Tarsus.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Portage Biotech
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Portage Biotech
Detailed financials for Portage Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Portage Biotech Comparisons
Peer comparison for Portage Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Portage Biotech
Detailed competitors of Portage Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Portage Biotech
Complete news archive for Portage Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Portage Biotech
Portage Biotech was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Portage Biotech is headquartered in Tortola, British Virgin Islands.
Alexander Pickett is the current CEO of Portage Biotech.
Portage Biotech was founded in 2013 in Tortola and operates in the biotechnology sector, focusing on pharmaceutical product development through clinical proof of concept. Emphasis is placed on orphan drugs and targeted therapies for cancer, infectious diseases, neurology, and psychiatry. Products are licensed or sold to larger firms post-proof. Subsidiaries include Portage Pharmaceuticals Ltd for CPP-based treatments and Biohaven for glutamatergic agents addressing neuropsychiatric disorders.
Portage Biotech offers iNKT Platform, Adenosine Platform, and Other Programs.
Yes, Portage Biotech is publicly traded on NASDAQ under the ticker symbol ATON.
Portage Biotech has made 2 acquisitions, including Tarsus Rx, and Tarus Therapeutics.
The ticker symbol of Portage Biotech is ATON on NASDAQ.